Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Maia Biotechnology Inc

MAIA ✓ COMPLIANTFree checks used up today ☆ Track — members

NYSE MKT · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.25

▼ -5.30%

Market Cap $77.25M · Vol 52.83K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$77.25M

Micro Cap

Div Yield

N/A

EPS Growth

+22.86%

YoY

RSI (14)

42.59

Momentum

Beta

0.27

vs Market

52W High

$3.16

60.44% below

52W Low

$0.87

43.68% above

Volume

52.83K

Avg 39.36K

P/B

24.87

Price-to-book

ROE

N/A

Return on equity

Free Float

85.19%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Maia Biotechnology Inc (MAIA) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does MAIA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-10.71%

-7.41%

-10.07%

-13.19%

YTD

-18.30%

-21.88%

-13.19%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-22,396,170.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-225.54% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	24.87
P/FCF	N/A
EPS Growth	+22.86%
Outstanding Shares	60.83M

Technical Indicators

50-Day SMA	$1.34
200-Day SMA	$1.50
RSI (14)	42.59
Beta	0.27
52-Week High	$3.16
52-Week Low	$0.87

Volume Today	52.83K
Avg Daily Volume (30D)	39.36K
Relative Volume	1.34x
Volatility (10D)	66.06
Volatility (30D)	49.63
Free Float	85.19%

Analyst Consensus

BUY

Current Price $1.25

Mean Target $12.00

52W Low$0.87 52W High$3.16

Current

Target

$0.87 $3.16

Current Analyst target

+860.00% upside potential · 1 analysts

Identifiers

ExchangeNYSE MKT

FIGIBBG0113Q7J97

ISINUS5526411021

CountryUSA

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 5, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +1.46% ONC BeOne Medicines AG -1.38% 068270.KS Celltrion, Inc. -0.62% MEDP Medpace Holdings, Inc. +0.56% ABVX Abivax SA +0.79%

Company Profile

MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine), is a lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in tumor regression in advanced, in vivo cancer models by induction of cancer type-specific immune memory. THIO is being developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.